Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting
Figure 6
The cost-effectiveness acceptability curves for the five first-line strategies.
(A) without the SPAP; (B) with the SPAP. The y-axis indicates the probability that a strategy is cost-effective across the willingness to pay per QALY gained (x-axis). The bold vertical dashed line represent the thresholds for China.